Brief: Kezar Announces Topline Results From PRESIDIO Trial Of Zetomipzomib For The Treatment Of Dermatomyositis And Polymyositis

Kezar Life Sciences

03/05/2022 21:49

May 3 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR ANNOUNCES TOPLINE RESULTS FROM PRESIDIO TRIAL OF
ZETOMIPZOMIB FOR THE TREATMENT OF DERMATOMYOSITIS AND
POLYMYOSITIS
    * KEZAR LIFE SCIENCES - TOPLINE DATA FROM MISSION PHASE 2
TRIAL OF
ZETOMIPZOMIB IN LN ON TRACK, EXPECTED IN JUNE 2022
    * KEZAR LIFE SCIENCES - ZETOMIPZOMIB DEMONSTRATES A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE

Source text for Eikon:  ID:nBw9vCzmca 
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))